RE: Is there a TA explanation for this £13 ceiling?7 Apr 2021 22:46
I believe there has been concerted efforts to control the GSK price since start of this year.
If you can read back some of Toff_Appleton's posts he riases a number of issues that point in this direction.
starting just before FY results, both CS and DB issued "sell notes" when all other brokers were neutral or positive.
This started a chain of down-turns in the SP, despite the majority of brokers being bullish.
There was a clear control at £14 that stopped any rises above that level, and when we got to ex div date the SP dropped swiftly with a further re-issue of these brokers sell notes and 1150 target.
From there the SP tumbled to below £12, consolidated around £12 then had a rapid-fire run to just below £13 where we have been controlled for about 4 weeks.
It seems the round £ levels of £12,13 and £14 all being used heavily to control the SP.
I thought we had broken above £13 a fortnight ago only to be dragged down like a magnet.
The SP is historically low for a company with these earnings and dividends.
The outlook is slow with the forthcoming split, and it seems unlikely we will be running back to the £15-£18 range we were in just 6 months ago, anytime before the business is restructured.
I am sure the directors are filling their boots with cheap options during 2021, and will reep excessive gains after the split in 2023. Meanwhile PIs just have to suffer and live off the scraps, and big institutions/investors sit on the shares while they are yielding 6% this year, with a future divi cut already priced in.
It is so disappointing that GSK has not been able to profit from a pendemic that should allow candy to be taken from a baby.
Burp as Shawz says
Cheers & GLA - CSDI